Info on Postmarketing Adverse Drug Reporting Sent to OMB
02/03/2016
Federal Register Notice: FDA’s collection of information entitled “Postmarketing Adverse Drug Experience Reporting” has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995. To view this notice, click here.
